

To: **Dandekar Clinic**  
 Agri Samaj Mandir Road, Old Panvel  
 Panvel Navi Mumbai - 410206  
 Maharashtra  
 Contact: 022-27452194  
**Report Of: APARNA AMIT PATIL**  
 Pt. Contact: 8454060799



|               |                            |
|---------------|----------------------------|
| Sample ID     | LI190024863                |
| Patient ID    | LI190246491                |
| Received on   | 11-03-2019 18:48           |
| Registered on | 11-03-2019 18:48           |
| Reported on   | 12-03-2019 15:49           |
| Referred by   | <b>Dr. Kanchan Divekar</b> |
| Sonography by |                            |


## EVICOSCREEN - EVIDENCE BASED COMPREHENSIVE PRENATAL SCREENING REPORT

Patient Name: \_\_\_\_\_ Patient DOB: \_\_\_\_\_

Ethnicity: \_\_\_\_\_ City: \_\_\_\_\_ Hospital ID: \_\_\_\_\_

**Sample Type:** Serum  
**Collection Date:** 11-03-2019

**Method:** Electrochemiluminescence (Roche)

**EVIC**  **Screen™** is an evidence based prenatal screening program curated by Lilac Insights in accordance with the Fetal Medicine Foundation (UK) guidelines for First Trimester Screening to determine the probability of most common chromosomal aneuploidies in a pregnancy. It utilizes:

- Hormonal values from the pregnancy measured on Fetal Medicine foundation (UK) accredited analyzers and reagents
- Robust indigenous medians from over 5 lac+ pregnancies for different gestation ages
- Risk calculations from evidence based algorithms validated through large international studies
- External audit of the prenatal screening program by United Kingdom National External Quality Assessment Service (UKNEQAS) scheme and Randox International Quality Assessment Scheme (RIQAS)

| Test Name  | Result          | Units |
|------------|-----------------|-------|
| AFP        | 17.30 (1.3 MoM) | U/mL  |
| Free β-hCG | 20.44           | ng/mL |
| PAPP-A     | 1730.00         | mU/L  |
| PLGF       | 10.44           | pg/mL |

### Note

1. These values should not be interpreted in isolation and need to be necessarily incorporated in validated prenatal Aneuploidy risk calculation software, along with ultrasound and biophysical parameters to calculate the patients individualised risk for aneuploidies and interpreted accordingly. We will appreciate you providing us the outcomes.
2. Divide the values for PAPP-A by 1000 for ASTRAIA Software.